Get the Stockscreener App
1.28
3.03%
-0.04
Pre-market:
1.26
-0.02
-1.56%
Lucid Diagnostics Inc stock is traded at $1.28, with a volume of 1.01M.
It is down -3.03% in the last 24 hours and down -5.88% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
1.01M
Relative Volume:
1.91
Market Cap:
$107.05M
Revenue:
$2.43M
Net Income/Loss:
$-52.67M
P/E Ratio:
-1.0159
EPS:
-1.26
Net Cash Flow:
$-33.04M
1W Performance:
-7.91%
1M Performance:
-5.88%
6M Performance:
+51.26%
1Y Performance:
+4.92%
1-Day Range:
$1.24
$1.35
1-Week Range:
$1.18
$1.41
52-Week Range:
$0.6301
$1.633
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.28 | 107.05M | 2.43M | -52.67M | -33.04M | -1.26 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Blue Cross Blue Shield backs esophageal cancer DNA test - Investing.com India
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - PR Newswire
Lucid Diagnostics Executes First Concierge Medicine Contract wit - GuruFocus.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Pri - GuruFocus.com
PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Trading Down 14.4% – Here’s Why - Defense World
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - BioSpace
Analyzing Embecta (NASDAQ:EMBC) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Understanding Lucid Diagnostics Inc (NASDAQ: LUCD)’s Growth Potential - Stocks Register
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow - Crain's New York Business
Lucid Diagnostics secures $15.3 million in stock offering By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - GuruFocus.com
Lucid Diagnostics secures $15.3 million in stock offering - Investing.com India
Lucid Diagnostics Raises $15.3 Million in Stock Offering - TipRanks
Has Lucid Diagnostics Secured Enough Capital? $15.3M Raised at $1.10 Per Share - StockTitan
Lucid Diagnostics secures $15.3 million in stock sale By Investing.com - Investing.com Australia
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering - The Eastern Progress Online
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Lucid Diagnostics announces registered direct offering - Medical Buyer
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus.com
Lucid Diagnostics Announces $15.3 Mln Direct Offering - Nasdaq
Lucid Diagnostics ends "at the market" equity offering By Investing.com - Investing.com South Africa
Lucid Diagnostics stock dips on $15.3M share offering - MSN
Lucid Diagnostics secures $15.3 million in stock sale - Investing.com India
Lucid Diagnostics Prices $15.3 Million Direct Offering -March 04, 2025 at 09:03 am EST - Marketscreener.com
Lucid Diagnostics Announces $15.3 Million Direct Offering - TipRanks
Lucid Diagnostics ends "at the market" equity offering - Investing.com India
Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering - TipRanks
Lucid Diagnostics Raises $15.3 Million Through Common Stock Offering at $1.10 Per Share - StockTitan
Can Lucid's Cancer Test Reach Millions More Patients? NIH Invests $8M to Find Out - StockTitan
Renowned Investigators Awarded $8 Million NIH Grant to Study Luc - GuruFocus.com
Lucid Diagnostics meets Nasdaq minimum bid price rule By Investing.com - Investing.com Australia
Lucid Diagnostics Restores Nasdaq Listing Compliance - Nasdaq
Lucid Diagnostics regains compliance with Nasdaq listing requirement - MSN
Lucid Diagnostics meets Nasdaq minimum bid price rule - Investing.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health -February 20, 2025 at 08:31 am EST - Marketscreener.com
Lucid Diagnostics secures concierge medicine contract By Investing.com - Investing.com Nigeria
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics secures concierge medicine contract - Investing.com
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health - Nasdaq
PAVmed regains compliance with Nasdaq Capital Market’s CLS - Medical Buyer
PAVMPavmed Latest Stock News & Market Updates - StockTitan
Innovative Tech Company Surges Forward: PAVmed Triumphs in Nasdaq Compliance - Smartphone Magazine
Navigating the High Seas of Market Compliance: PAVmed’s Resilient Return - Mi Valle
PAVmed Triumphs on Nasdaq: A Medical Tech Comeback Story - Jomfruland.net
Critical Victory: PAVmed's Strategic Moves Save Nasdaq StatusFull Details Inside - StockTitan
SI-BONE (NASDAQ:SIBN) vs. Lucid Diagnostics (NASDAQ:LUCD) Head to Head Survey - Defense World
Lucid Diagnostics stock hits 52-week high at $1.5 amid growth optimism - MSN
Lucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review - Defense World
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):